COMPANY

Polaryx Therapeutics

Keywords: small molecule neuronal ceroid lipofuscinosis 2 neuronal ceroid lipofuscinosis 3 Krabbe disease Juvenile Neuronal Ceroid Lipofuscinosis Lysosomal Storage Disorders Sandhoff Disease CLN2 CLN3 PLX-200

Location: Paramus, NJ · source · Oct 14, 2026

Profile checked Oct 10, 2026

$10.0MRaised (2 yrs)2Trials (company is sponsor)

Timeline

Dec 1, 2026 Trial start Phase 2: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol) source ↗
Nov 1, 2026 Trial start Phase 3: Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3 source ↗
May 28, 2026 Raise Private placement: $10M (total, as published), announced May 28, 2026. Source: company release on GlobeNewswire. source ↗

Upcoming milestones

Dec 31, 2028 (ESTIMATED) · Phase 2 · Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol) · NCT07740512

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $10.0M. Last 2 years.

May 28, 2026 Private placement: $10M (total, as published), announced May 28, 2026. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT04637282	Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3	Phase 3	Withdrawn	Nov 1, 2026	Dec 31, 2026 (estimated)
NCT07740512	Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)	Phase 2	Not yet recruiting	Dec 1, 2026	Dec 31, 2028 (estimated)